biostudies-literatureUnknown60Cham S<h4>Purpose</h4>Uterine carcinosarcoma (UCS) is a rare but aggressive tumor with high rates of recurrence and poor prognosis, and novel therapies are urgently needed. P53 mutations are identified in over 90% of cases, and other cell cycle alterations are commonly found indicating potential vulnerability to Wee1 kinase inhibition. The purpose of this study was to determine the activity and safety of adavosertib, a Wee1 inhibitor, in recurrent or persistent UCS.<h4>Patients and methods</h4>This was a phase II single-institution study of patients with persistent or recurrent UCS. Eligible patients had a confirmed <i>TP53</i> alteration, RECIST measurable disease, and prior treatment with platinum based systemic therapy. Patients were treated with adavosertib at a starting dose of 300 mg orallGynecologic oncology reports101796https://www.ebi.ac.uk/biostudies/studies/S-EPMC12269869biostudies-literaturePhase 2 study of Wee1 inhibitor adavosertib in recurrent uterine carcinosarcoma.PMC12269869Sawyer HTayob NMatulonis UAXiong NMathews CLee EKKonstantinopoulos PALiu JFKrasner CWright AACham SfalsePhase 2 study of Wee1 inhibitor adavosertib in recurrent uterine carcinosarcoma.<h4>Purpose</h4>Uterine carcinosarcoma (UCS) is a rare but aggressive tumor with high rates of recurrence and poor prognosis, and novel therapies are urgently needed. P53 mutations are identified in over 90% of cases, and other cell cycle alterations are commonly found indicating potential vulnerability to Wee1 kinase inhibition. The purpose of this study was to determine the activity and safety of adavosertib, a Wee1 inhibitor, in recurrent or persistent UCS.<h4>Patients and methods</h4>This was a phase II single-institution study of patients with persistent or recurrent UCS. Eligible patients had a confirmed <i>TP53</i> alteration, RECIST measurable disease, and prior treatment with platinum based systemic therapy. Patients were treated with adavosertib at a starting dose of 300 mg orall2025-01-01T00:00:00Z2025 Aug2026-03-27T15:50:36.159Z2025-08-27T03:06:59.038ZS-EPMC122698694067857710.1016/j.gore.2025.101796